• Norsk
  • English

Aktuelt

Press release - Oxford Gene Technology

Oxford, UK – 22nd February 2012 – Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, announced today that it has entered into an exclusive licensing agreement with Inven2, the technology transfer office at Oslo University Hospital (OUS) and University of Oslo (UiO), for 12 highly promising colorectal cancer tissue biomarkers.

Press release - AIMS innovation

AIMS Innovation - provider of proactive Microsoft Biztalk monitoring - announces completion of first round seed funding

Oslo, Norway, September 20, 2011 – AIMS Innovation, provider of proactive Microsoft Biztalk monitoring, announces the completion of the first round of seed funding. The financing round was led by PROG Invest, a single purpose investment vehicle represented by Mr. Tor Bækkelund, and also included participation from Inven2, Oslo Innovation Center and Mr. Ivar Sagemo.

Press release - Ultimovacs

Biotekselskapet Ultimovacs støttes av Gjelsten i utviklingen av fremtidsrettet kreftvaksine

(Oslo, 11. mai 2011) Biotekselskapet Ultimovacs AS har hentet kapital for videre utvikling av en unik terapeutisk kreftvaksine basert på forskning fra Oslo universitetssykehus og Universitetet i Oslo. Forretningsmannen og investoren Bjørn Rune Gjelsten er hovedinvestor, og går selv inn i styret sammen med sin partner Ketil Fjerdingen som blir styreleder i selskapet.

Press release - Novozymes

Novozymes Biopharma collaborates with the University of Oslo to develop enhanced albumin fusion technology that tailors the half-life of proteins

Albufuse® Flex next-generation technology has been developed to tailor and control the pharmacokinetics of target proteins and peptides for flexible, optimal use.

INVEN2-PRISEN

Har du en idé til nytt produkt eller tjeneste?

Send inn din idé og vinn 100.000 kroner til utvikling av idéen.

Pages